PATENT CLAIM ANALYSIS

Application Number: 15746050
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-10
Patent Classification: ["424", "134100"]

Abstract:
The present invention relates to agents for reducing the activity of GDF15 and in particular the use of such agents to treat or prevent conditions associated with elevated or unwanted levels of GDF15. The invention is based on the discovery that GDF15 binds to the receptors CLPTM1 and QRFPR and provides agents for such use in the form of binding agents capable of binding to the receptors and inhibiting the interaction between GDF15 and the receptor. Further agents include polypeptides derived from the receptors which are capable of binding to GDF15 and inhibiting its interaction with the receptors. Also provided are diagnostic methods based on detecting the interaction or an effect thereof, and cytotoxic immune cells modified to have a reduced level and/or activity of CLPTM1.

Claim (Index 85):
The method of  claim 63 , wherein the polypeptide for use or polypeptide has or comprises the sequence as set forth in any one of SEQ ID NOs:30, 31, 32, 39, 46, 47 or 175-189 or a sequence having at least 75% sequence identity thereto.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 86.0
- Lexical Diversity: 1.87143
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15714015', '13078728', '15044883', '13974792', '15231309']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6938683926614321
- 35 USC 102 Novelty (BERT): 0.5241426885280929
- Combined Prediction Score: 0.6768958222480982
- Mean Citation Score: 281.044742
- Max Citation Score: 292.85443
- Similarity Product: 192.8306125538939

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test